1530 related articles for article (PubMed ID: 2239801)
1. Phase II study of recombinant alpha-interferon in malignant melanoma.
Neefe JR; Legha SS; Markowitz A; Salmon S; Meyskens F; Groopman J; Campion M; Evans L
Am J Clin Oncol; 1990 Dec; 13(6):472-6. PubMed ID: 2239801
[TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of recombinant interferon alfa-2a (Roferon-A) in metastatic melanoma using two different schedules .
Legha SS; Papadopoulos NE; Plager C; Ring S; Chawla SP; Evans LM; Benjamin RS
J Clin Oncol; 1987 Aug; 5(8):1240-6. PubMed ID: 3625246
[TBL] [Abstract][Full Text] [Related]
3. A phase I-II trial of the combination of recombinant leukocyte A interferon and recombinant human interferon-gamma in patients with metastatic malignant melanoma.
Creagan ET; Loprinzi CL; Ahmann DL; Schaid DJ
Cancer; 1988 Dec; 62(12):2472-4. PubMed ID: 3142675
[TBL] [Abstract][Full Text] [Related]
4. Treatment of metastatic malignant melanoma with recombinant interferon alpha 2.
Robinson WA; Mughal TI; Thomas MR; Johnson M; Spiegel RJ
Immunobiology; 1986 Sep; 172(3-5):275-82. PubMed ID: 3804370
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of a combination of interferon-beta ser and interferon-gamma in patients with advanced malignant melanoma.
Schiller JH; Storer B; Bittner G; Willson JK; Borden EC
J Interferon Res; 1988 Oct; 8(5):581-9. PubMed ID: 3148669
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of recombinant leukocyte A interferon (rIFN-alpha A) in disseminated malignant melanoma.
Creagan ET; Ahmann DL; Green SJ; Long HJ; Rubin J; Schutt AJ; Dziewanowski ZE
Cancer; 1984 Dec; 54(12):2844-9. PubMed ID: 6498762
[TBL] [Abstract][Full Text] [Related]
7. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study.
Lee KH; Talpaz M; Rothberg JM; Murray JL; Papadopoulos N; Plager C; Benjamin R; Levitt D; Gutterman J
J Clin Oncol; 1989 Nov; 7(11):1726-32. PubMed ID: 2809685
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of 5-fluorouracil and recombinant alpha 2a-interferon in patients with advanced colorectal carcinoma.
Wadler S; Goldman M; Lyver A; Wiernik PH
Cancer Res; 1990 Apr; 50(7):2056-9. PubMed ID: 2317795
[TBL] [Abstract][Full Text] [Related]
9. Phase II trials of recombinant leukocyte A interferon in disseminated malignant melanoma: results in 96 patients.
Creagan ET; Ahmann DL; Frytak S; Long HJ; Chang MN; Itri LM
Cancer Treat Rep; 1986 May; 70(5):619-24. PubMed ID: 3518925
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of recombinant leukocyte A interferon in advanced malignant melanoma.
Elsässer-Beile U; Drees N; Neumann HA; Schöpf E
J Cancer Res Clin Oncol; 1987; 113(3):273-8. PubMed ID: 3584216
[TBL] [Abstract][Full Text] [Related]
11. Studies of interferons in the therapy of melanoma.
Kirkwood JM
Semin Oncol; 1991 Oct; 18(5 Suppl 7):83-90. PubMed ID: 1948134
[TBL] [Abstract][Full Text] [Related]
12. Dacarbazine and interferon alpha for stage IV malignant melanoma.
Tamm I; Grimme H; Bergen E; Simon JC; Schöpf E; Mertelsmann R; Lindemann A; Brennscheidt U
Oncology; 1997; 54(4):270-4. PubMed ID: 9216849
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of recombinant alpha-2b-interferon and low-dose cyclophosphamide in advanced melanoma and renal cell carcinoma.
Wadler S; Einzig AI; Dutcher JP; Ciobanu N; Landau L; Wiernik PH
Am J Clin Oncol; 1988 Feb; 11(1):55-9. PubMed ID: 3277375
[TBL] [Abstract][Full Text] [Related]
14. Recombinant leukocyte A interferon (rIFN-alpha A) in the treatment of disseminated malignant melanoma. Analysis of complete and long-term responding patients.
Creagan ET; Ahmann DL; Frytak S; Long HJ; Itri LM
Cancer; 1986 Dec; 58(12):2576-8. PubMed ID: 3779607
[TBL] [Abstract][Full Text] [Related]
15. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Kirchner HH; Atzpodien J; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous low-dose interleukin-2 plus alpha interferon in advanced malignant melanoma.
de Braud F; Biganzoli L; Bajetta E; Colleoni M; Zampino MG
Tumori; 1993 Jun; 79(3):187-90. PubMed ID: 8236501
[TBL] [Abstract][Full Text] [Related]
17. Recombinant interferon alfa-2a in advanced malignant melanoma. A phase I-II study in combination with DTIC.
McLeod GR; Thomson DB; Hersey P
Int J Cancer Suppl; 1987; 1():31-5. PubMed ID: 3476475
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of interferon alpha-2a and dacarbazine in advanced melanoma.
Bajetta E; Negretti E; Giannotti B; Brogelli L; Brunetti I; Sertoli MR; Bernengo MG; Sofra MC; Maifredi G; Zumiani G
Am J Clin Oncol; 1990 Oct; 13(5):405-9. PubMed ID: 2220660
[TBL] [Abstract][Full Text] [Related]
19. Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation.
Figlin RA; deKernion JB; Mukamel E; Palleroni AV; Itri LM; Sarna GP
J Clin Oncol; 1988 Oct; 6(10):1604-10. PubMed ID: 3049952
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of low-dose recombinant leukocyte A interferon in disseminated malignant melanoma.
Creagan ET; Ahmann DL; Green SJ; Long HJ; Frytak S; O'Fallon JR; Itri LM
J Clin Oncol; 1984 Sep; 2(9):1002-5. PubMed ID: 6470751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
